Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity.

Dai S, Schantz A, Clements-Egan A, Cannon M, Shankar G.

AAPS J. 2014 May;16(3):464-77. doi: 10.1208/s12248-014-9581-z. Epub 2014 Mar 5.

2.

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.

Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J.

Pain. 2013 Oct;154(10):1910-9. doi: 10.1016/j.pain.2013.05.051. Epub 2013 Jun 5. Erratum in: Pain. 2014 Jan;155(1):204.

PMID:
23748114
3.

Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.

Weeraratne DK, Lofgren J, Dinnogen S, Swanson SJ, Zhong ZD.

J Immunol Methods. 2013 Oct 31;396(1-2):44-55. doi: 10.1016/j.jim.2013.07.010. Epub 2013 Aug 6.

PMID:
23933325
4.

False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay.

Chen K, Page JG, Schwartz AM, Lee TN, DeWall SL, Sikkema DJ, Wang C.

J Immunol Methods. 2013 Aug 30;394(1-2):22-31. doi: 10.1016/j.jim.2013.04.011. Epub 2013 Apr 29.

PMID:
23639298
5.

A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.

Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S.

J Immunol Methods. 2015 Nov;426:62-9. doi: 10.1016/j.jim.2015.08.002. Epub 2015 Aug 6.

PMID:
26255760
6.

Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.

Mikulskis A, Yeung D, Subramanyam M, Amaravadi L.

J Immunol Methods. 2011 Feb 28;365(1-2):38-49. doi: 10.1016/j.jim.2010.11.011. Epub 2010 Dec 1.

PMID:
21130095
7.

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T.

J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29.

PMID:
21824477
8.

Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.

Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J.

J Pharm Biomed Anal. 2010 Jun 5;52(2):249-54. doi: 10.1016/j.jpba.2009.12.029. Epub 2010 Jan 4.

PMID:
20083366
9.

Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.

Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, DeSilva BS, Arnold ME, Zeng J, Dodge RW.

J Immunol Methods. 2015 Jan;416:94-104. doi: 10.1016/j.jim.2014.11.005. Epub 2014 Nov 8.

PMID:
25445325
10.

Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.

Leite VF, Buehler AM, El Abd O, Benyamin RM, Pimentel DC, Chen J, Hsing WT, Mazloomdoost D, Amadera JE.

Pain Physician. 2014 Jan-Feb;17(1):E45-60. Review.

11.

Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.

Li J, Schantz A, Schwegler M, Shankar G.

J Pharm Biomed Anal. 2011 Jan 25;54(2):286-94. doi: 10.1016/j.jpba.2010.08.022. Epub 2010 Sep 24.

PMID:
20869832
12.

Identification and inhibition of drug target interference in immunogenicity assays.

Zhong ZD, Dinnogen S, Hokom M, Ray C, Weinreich D, Swanson SJ, Chirmule N.

J Immunol Methods. 2010 Apr 15;355(1-2):21-8. doi: 10.1016/j.jim.2010.02.008. Epub 2010 Feb 24.

PMID:
20188106
13.

Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.

Araujo J, Zocher M, Wallace K, Peng K, Fischer SK.

J Pharm Biomed Anal. 2011 Jul 15;55(5):1041-9. doi: 10.1016/j.jpba.2011.03.008. Epub 2011 Mar 11.

PMID:
21466939
14.

Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.

Schwickart M, Mehrzai F, Pearson J, Shaghasi N, Chavez C, Schneider A, Wu S, Roskos L, Liang M.

J Immunol Methods. 2014 Jan 31;403(1-2):52-61. doi: 10.1016/j.jim.2013.11.018. Epub 2013 Nov 25.

15.

An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.

Wu Y, Liu X, Chen Y, Woods R, Lee N, Yang H, Chowdhury P, Roskos LK, White WI.

J Pharm Biomed Anal. 2013 Dec;86:73-81. doi: 10.1016/j.jpba.2013.06.005. Epub 2013 Jun 28.

PMID:
23988731
16.

Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?

Bannwarth B, Kostine M.

Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6.

PMID:
24691709
18.

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.

Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T.

J Immunol Methods. 2015 Mar;418:29-38. doi: 10.1016/j.jim.2015.01.007. Epub 2015 Jan 27.

PMID:
25637408
20.

Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.

Jiang H, Xu W, Titsch CA, Furlong MT, Dodge R, Voronin K, Allentoff A, Zeng J, Aubry AF, DeSilva BS, Arnold ME.

Anal Chem. 2014 Mar 4;86(5):2673-80. doi: 10.1021/ac5001465. Epub 2014 Feb 17.

PMID:
24506335
Items per page

Supplemental Content

Write to the Help Desk